Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells.
In a previous study we described a correlation between the metastatic potential of transformed rat embryo cells (REC) and their release of type IV collagenolytic activity (S. Garbisa et al., Cancer Res., 47: 1523-1528, 1987). In the present study, we have identified a Mr 92,000 gelatinase released exclusively by metastatic cell lines in vitro; seven of eight highly metastatic REC lines transformed by H-ras or H-ras plus v-myc released this enzyme. In contrast, the Mr 92,000 gelatinase was not detected in two separate nontumorigenic REC lines immortalized with H-ras or c-myc or in four independent tumorigenic REC lines (transformed by H-ras plus adenovirus E1A) with markedly reduced metastatic potential. Study of the Mr 92,000 gelatinase in tumor explants showed that its expression may be modulated in vivo. Not only was Mr 92,000 release enhanced in tumor explants from cell lines which released it in vitro, but its expression was evident in three primary tumors and six metastatic tumors from the one metastatic cell line that failed to release it in vitro. Explants from the nonmetastatic cell lines grown as tumors showed no Mr 92,000 gelatinase release. The heterogeneous expression of a number of other gelatinases with molecular weights of 52,000, 56,000, 62,000, 68,000, 80,000, and 240,000 was observed, but no correlation with metastatic potential was apparent. The Mr 92,000 gelatinase had the characteristics of a secreted neutral metalloproteinase. It may be responsible for the type IV collagenolytic activity reported previously in conditioned medium from metastatic transformed REC and could in part be responsible for the differences in metastatic potential in these cell lines.